Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( (HK:6990) ).
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has announced its upcoming annual general meeting scheduled for June 20, 2025. Key agenda items include the approval of financial and annual reports for 2024, re-appointment of auditors, remuneration plans for directors and supervisors, and the election of new non-executive and independent non-executive directors for the board. The meeting will also address the acquisition of wealth management products and amendments to procedural rules, indicating strategic planning and governance focus.
The most recent analyst rating on (HK:6990) stock is a Buy with a HK$219.74 price target. To see the full list of analyst forecasts on Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H stock, see the HK:6990 Stock Forecast page.
More about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a biopharmaceutical company based in China, focusing on the development and commercialization of innovative drugs and therapies. The company operates within the pharmaceutical industry, providing a range of biopharmaceutical products and services.
Average Trading Volume: 701,173
Technical Sentiment Signal: Buy
Current Market Cap: HK$75.23B
For a thorough assessment of 6990 stock, go to TipRanks’ Stock Analysis page.